Pharmaceutical Companies

Under the agreement, AstraZeneca will pay US$40 million upfront, with an additional US$1.46 billion available in development and commercial milestone payments.

The acquisition will enable Cotecna to serve pharmaceutical companies with a broader range of regulatory compliant testing services, while improving its capacity to respond to customer requirements across key markets.

The randomised, triple-blind, placebo-controlled trial enrolled 66 women aged 30 to 65 with hyperpigmented facial spots.

Both executives previously held leadership positions at Moderna, where they worked on messenger RNA (mRNA) cancer vaccines, including mRNA-4157/V940.

Lixudebart targets Claudin-1, a protein associated with tissue fibrosis, the process through which excessive scar tissue accumulates and damages organs.

The project will replace existing buildings with new facilities designed to support clinical development, commercial production and advanced manufacturing technologies.

The agreements cover cardiovascular disease, diabetes and oncology, with provisions for licensing, technology transfer and local manufacturing partnerships.

The premiere brought together respiratory and rheumatology specialists, including Dr Bassam Mahboub, Vice President of the Emirates Thoracic Society (ETS), and Dr Shamma Al Nokhatha, President of the Emirates Society for Rheumatology (ESR).

Under the agreement, the companies will identify and implement targeted applications of agentic AI, an AI systems designed to perform tasks and execute workflows with varying degrees of autonomy.

Located in Kendall Square, a major biotechnology and life sciences hub, the new centre will operate alongside AstraZeneca’s genomic medicine facility at 100 Binney Street.